Financial Performance - Revenue for 2023 increased to RMB 412,004 thousand, up from RMB 314,054 thousand in 2022[6] - Gross profit for 2023 was RMB 251,335 thousand, compared to RMB 212,741 thousand in 2022[6] - Profit for the year in 2023 was RMB 251,760 thousand, significantly higher than RMB 126,421 thousand in 2022[6] - Profit attributable to owners of the parent in 2023 was RMB 242,301 thousand, up from RMB 117,321 thousand in 2022[6] - Revenue for the year ended 31 December 2023 was RMB412.0 million, a 31.2% increase compared to the previous year[19] - Net profit for 2023 increased by 99.1% to RMB251.8 million, with a net profit margin of 61.1%, up 20.8 percentage points from 2022[19] - Adjusted net profit for 2023 was RMB271.1 million, an 86.8% increase from 2022, with an adjusted net profit margin of 65.8%, up 19.6 percentage points[19] - Revenue from precision marketing and corporate solutions grew by 29.3% to RMB372.7 million in 2023[23] - Revenue from medical knowledge solutions increased by 31.6% from RMB12.3 million in 2022 to RMB16.1 million in 2023[65][66] - Revenue from intelligent patient management solutions grew by 70.2% from RMB13.6 million in 2022 to RMB23.2 million in 2023[67][68] - Cost of sales increased by 58.6% from RMB101.3 million in 2022 to RMB160.7 million in 2023[69] - Gross profit rose by 18.1% to RMB251.3 million in 2023, but gross profit margin decreased from 67.7% in 2022 to 61.0% in 2023[69] - Other income and gains surged to RMB188.5 million in 2023, up from RMB75.7 million in 2022[69] - Selling and distribution expenses increased by 13.4% from RMB28.9 million in 2022 to RMB32.8 million in 2023[70] - Administrative expenses grew by 18.0% from RMB122.4 million in 2022 to RMB144.5 million in 2023[71][72] - The Group's profit before tax increased by approximately 87.5% from RMB135.0 million in 2022 to RMB253.1 million in 2023[73] - The Group's profit for the year increased by approximately 99.1% from RMB126.4 million in 2022 to RMB251.8 million in 2023[73] - The Group's net profit margin increased by 20.8 percentage points from 40.3% in 2022 to 61.1% in 2023[74] - Adjusted net profit for the year ended 31 December 2023 was approximately RMB271.1 million, an increase of approximately 86.8% compared to RMB145.2 million in 2022[77] - The adjusted net profit margin for the year ended 31 December 2023 was approximately 65.8%, up 19.6 percentage points from 46.2% in 2022[77] - The Group's income tax expense decreased by approximately 84.1% from RMB8.6 million in 2022 to RMB1.4 million in 2023[73] - The Group's finance costs decreased from approximately RMB0.5 million in 2022 to approximately RMB0.4 million in 2023[73] - Share-based compensation added to adjusted net profit was RMB10.4 million in 2023, compared to RMB17.2 million in 2022[76] - Fair value adjustment of contingent consideration added to adjusted net profit was RMB2.2 million in 2023, compared to RMB1.2 million in 2022[76] - Foreign exchange difference added to adjusted net profit was RMB6.8 million in 2023, compared to RMB0.3 million in 2022[76] User and Platform Growth - Medlive platform reached a record high of 6.8 million registered users, including over 4 million licensed physicians, accounting for 87% of the total licensed physicians in China[9] - Medlive's registered user base reached 6.8 million, including over 4.0 million licensed physicians, covering 87% of China's licensed physicians[11][16] - The Medlive platform achieved an average of 2.4 million monthly active users (MAUs) in 2023[16] - Medlive's platform meets physicians' needs in clinical diagnosis, professional learning, and medical research with high-quality content and tools[16] - Medlive's platform is widely recognized by Chinese physicians and medical professionals as the most popular professional medical platform[16] - The number of customers for precision marketing and corporate solutions increased by 40.0% to 182 in 2023, up from 130 in 2022[23] - The number of products covered in precision marketing solutions increased from 284 in 2022 to 386 in 2023[23] - Engaged targeted physicians increased from 627,000 in 2022 to 774,000 in 2023[23] - Paid clicks increased from 7.2 million in 2022 to 9.7 million in 2023[23] - The number of clients covered by the company's solution increased by 40.0% from 130 in 2022 to 182 in 2023[24] - The number of products covered rose from 284 in 2022 to 386 in 2023[24] - Registered physician users converted to paid clicks grew from 627,000 in 2022 to 774,000 in 2023[24] - Paid clicks increased from 7.2 million in 2022 to 9.7 million in 2023[24] - The Group's chronic disease management services platform had accumulated approximately 377,000 users and 105,000 participating physicians as of December 31, 2023[45] - The return consultation rate of patients and the average dosage and frequency of medication have increased significantly after implementing the physician-patient management solution[47] AI and Technology Integration - Medlive's self-developed AI large models for specific verticals have been successfully commercialized and applied in critical scenarios[13][14] - Medlive's AI technology enhances efficiency in patient education and academic promotion for pharmaceutical and medical device companies[13][14] - The company developed a vertical AI model in 2023, integrating healthcare industry expertise to enhance AI applications in medical translation, information search, and literature organization[17] - Medlive 3.0, an intelligent medical consulting system, was successfully commercialized, providing professional information support and improving physician loyalty and operational efficiency[18] - The company's digital tools, including decentralized clinical trial (DCT) systems and AI-equipped journal selection, enhanced clinical research efficiency[30] - The company's clinical research team has expanded significantly, leveraging digital tools such as remote intelligent clinical trial systems (DCT) and AI-assisted journal selection to enhance efficiency in clinical research processes[32] - The company embedded a literature assistant into its AI model, offering features like document summarization, interpretation, and PDF translation[40] - The company launched the eClinicalResearch platform to enhance physicians' research efficiency, including SCI manuscript submission with AI journal selection[40] - The company's eBroadcasting platform translated 70,000 videos with over 98% accuracy using large model technology[39] Strategic Investments and Acquisitions - The company capitalized on industry transformation and market opportunities, enhancing the integration of technology and healthcare[9] - Medlive's strategic investments in 2023 yielded satisfactory outcomes, enriching solutions for pharmaceutical and medical device companies[12][14] - The company acquired 60% equity interest in Beijing Medcon for RMB 100,253,400, with the consideration paid in four installments totaling RMB 90,220,000 as of 2023[92][93] - Beijing Medcon's audited net profit for 2022 and 2023 exceeded RMB 17,000,000 and RMB 19,540,000 respectively, resulting in no adjustment to the acquisition consideration[92][93] - The company acquired 50% equity interest in SCMedcon for RMB 65,000,000, with the first installment of RMB 35,750,000 already paid[94][95] - SCMedcon's sellers guaranteed a cumulative audited net profit of at least RMB 58,080,000 for the years 2023-2026, with the consideration adjustable if the target is not met[95] - The company acquired 60% equity interest in Linberg Consulting for RMB 33,930,000, with the first installment of RMB 17,000,000 already paid[97][98] - Linberg Consulting's sellers guaranteed a cumulative audited net profit of at least RMB 21,720,000 for the years 2023-2026, with the consideration adjustable if the target is not met[98] - The company plans to continue pursuing strategic investments and acquisitions to generate synergies, expand its customer base, and enhance technological capabilities[99][100] - The Group raised approximately RMB4,677 million from its global offering in July 2021, with RMB640.4 million utilized by 31 December 2023 and RMB4,036.1 million remaining for future use[86][87] - The Group's capital expenditure for 2023 amounted to approximately RMB88.2 million, primarily for acquisitions and IT equipment, compared to RMB46.0 million in 2022[89][90] Regulatory and Market Environment - Regulatory policies in the pharmaceutical industry, including volume-based procurement and medical insurance negotiations, brought new opportunities for innovative drugs and digital marketing[10] - The company is subject to evolving regulatory requirements in China, particularly in healthcare, digital healthcare, and internet-related businesses, which could adversely affect its operations[144] - The company faces high customer concentration risks, with a limited number of pharmaceutical and medical device customers contributing significantly to its revenues[141] - The company's clinical research services rely on hospitals and physicians to update healthcare data, but it cannot guarantee the accuracy, quality, or timeliness of such data[143] - The company may face claims or liabilities related to its patient recruitment service if patients incur injuries from tested drugs or devices[143] Employee and Management Structure - The Group had a total of 742 full-time employees as of 31 December 2023, with 186 in content management, 239 in platform operation and customer service, 176 in research and development, 63 in general and administration, and 78 in sales and marketing[101] - Total staff costs for the year ended 31 December 2023 were approximately RMB159.2 million, an increase from RMB152.8 million in 2022, primarily due to increased headcount in sales and platform development staff[101] - The Group provides orientation and ongoing in-house training for employees, and compensates them with base salaries, performance-based bonuses, and share incentive schemes including pre-IPO and post-IPO share option schemes and a share award scheme[101] - Ms. Tian Liping, aged 57, is the Chairwoman, CEO, and an executive Director of the Company, responsible for formulating and implementing the Group's overall development strategies and business plans[102] - Mr. Tian Lixin, aged 55, is the President, head of the Medical Information Science Research Unit, and an executive Director, responsible for overseeing and managing the Group's operations[103][104] - Mr. Tian Lijun, aged 50, is an executive Director, vice president, and deputy head of the Medical Information Science Research Unit, responsible for overseeing and managing the research, development, and innovation of the Group's products and technologies[105][106] - Ms. Zhou Xin, aged 43, is an executive Director and vice president, responsible for overseeing and managing the Group's digital marketing operations and multichannel business development in healthcare marketing[107] - Ms. Zhou Xin, aged 43, is the Executive Director and Vice President of the company, overseeing digital marketing and medical marketing with over 18 years of marketing strategy and business management experience[108] - Mr. Eiji Tsuchiya, aged 59, is a Non-Executive Director with over 37 years of experience in insurance and financial consulting, and over 17 years in the healthcare technology industry[109][110] - Mr. Tsuchiya joined M3, Inc. in August 2006 and currently serves as an Executive Director of M3, Inc., a company listed on the Tokyo Stock Exchange (Stock Code: 2413.T)[111] - Mr. Kazutaka Kanairo, aged 46, is a Non-Executive Director with over 12 years of experience in M&A and corporate development, and over 11 years in management advisory[111] - Mr. Kanairo joined M3, Inc. in March 2014 and is currently the head of India & Southeast Asia business and director of global corporate development at M3, Inc.[111] - Mr. Richard Yeh, aged 55, is an independent non-executive Director of the company, responsible for providing independent advice to the Board[112] - Mr. Yeh served as the chief financial officer of CStone Pharmaceuticals (Stock Code: 2616) from July 2018 to April 2020[112] - Dr. Ma Jun, aged 69, is an independent non-executive Director of the company, responsible for providing independent advice to the Board[112] - Dr. Ma has been the chairman of the board of supervisors of the China Society of Clinical Oncology (CSCO) since September 2019[114] - Ms. Wang Shan, aged 50, is an independent non-executive Director of the company, responsible for providing independent advice to the Board[115] - Ms. Wang retired in September 2023 after working at Hitachi Solutions (China) Co., Ltd. from November 2022 to September 2023[115] - Mr. Xin Jiangtao, aged 47, is a vice president of the Group, responsible for the research and development and innovation of the Group's products and services[118] - Mr. Xin has over 20 years of medical software development experience[118] - Mr. Yang Liancheng, aged 45, is a vice president of the Group, responsible for executing overall development strategies and business plans of the Group[119] - Mr. Yang has over 19 years of experience in consulting and over five years of experience in the medical information technology industry[119] - Mr. Yang holds a bachelor's degree in trade and economics from Nankai University, a master's degree in finance from Peking University, and an EMBA from China Europe International Business School[120] - Mr. Xin Jiangtao, Vice President, has over 20 years of experience in medical software development and holds a bachelor's degree in Computer Science and Technology from Peking University[121] - Mr. Yang Liancheng, Vice President, has over 19 years of consulting experience and 5 years in the medical information technology industry, with degrees from Nankai University and Peking University[121] - Mr. Jiang Nan, Medical Director, has over 10 years of experience in the medical information technology industry and holds degrees in clinical medicine and psychiatry from Qingdao University and Peking University[122][123] - Ms. Liu Juan, Chief Client Officer, has approximately 16 years of experience in human resources management and holds a bachelor's degree in business administration and an MBA[124][125] - Ms. Yang Yanling, Joint Company Secretary, has experience in human resources management and holds a bachelor's degree in agriculture from Hebei North University[127] - Ms. Chu Cheuk Ting, Joint Company Secretary, has over 12 years of experience in the professional company secretarial field and is an associate member of The Hong Kong Chartered Governance Institute[129] Share Incentive Schemes - The total number of shares available for issue under the Post-IPO Share Option Scheme is 69,017,600 shares, representing 9.49% of the total issued shares as of December 31, 2023[157] - The Group has three share incentive schemes: Post-IPO Share Option Scheme, Pre-IPO Share Option Scheme, and Share Award Scheme, regulated under Chapter 17 of the Listing Rules[157] - The Post-IPO Share Option Scheme was approved on June 18, 2021, to incentivize and reward employees and directors for their contributions to the Group[157] - No share options were granted, vested, exercised, cancelled, or lapsed under the Post-IPO Share Option Scheme during the year ended 31 December 2023, and there are no outstanding share options under the scheme[163] - The total number of options and share awards available for grant under the Post-IPO Share Option Scheme and the Share Award Scheme as of 1 January 2023 and 31 December 2023 is 69,017,600, representing approximately 9.49% of the company's issued share capital[163] - The remaining life of the Post-IPO Share Option Scheme is approximately 7.5 years as of 31 December 2023[161] - The Pre-IPO Share Option Scheme has a remaining life of approximately 2.5 years as of 31 December 2023[165] - The total number of shares that may be issued upon exercise of all Pre-IPO Share Options granted under the Pre-IPO Share Option Scheme must not exceed 26,754,000 shares, representing 3.68% of the company's issued share capital and 3.71% of the weighted average number of shares in issue during the year ended 31 December 2023[165] - The exercise price per share for Pre-IPO Share Options is RMB 0.38, determined based on the company's net asset value and historical financial performance prior to listing[165] - Pre-IPO share options totaling 26,754,000 shares, representing 3.68% of the issued share capital, were granted to 62 grantees on 2 April 2021[166] - The weighted average closing price of shares before the exercise of Pre-IPO share options during 2023 was HK$7.39[168] - The Share Award Scheme, effective from 24 December 2021, allows for the issuance of up to 69,517,600 shares, representing approximately 9.56% of the total issued shares as of 31 December 2023[170] - The grant price for share awards under the Share Award Scheme is US$0.00001 per share, with vesting conditions including a minimum holding period of one year and up to 10 years[169] - The Share Award Scheme Mandate Limit can be refreshed with shareholder approval, and no individual participant can be granted awards exceeding 1% of the issued shares in a 12-month period without shareholder approval[170] - The Share Award Scheme has a remaining life of approximately 8 years as of 31 December 202

Revenue Growth - Revenue increased by 31.2% to RMB 412,004 thousand in 2023 compared to RMB 314,054 thousand in 2022[2] - Revenue from precision marketing and enterprise solutions increased by 29.3% to RMB 372,687 thousand in 2023 from RMB 288,177 thousand in 2022[3] - Revenue from intelligent patient management solutions surged by 70.2% to RMB 23,176 thousand in 2023 from RMB 13,616 thousand in 2022[3] - The company's revenue for 2023 reached approximately RMB 412.0 million, a year-on-year increase of 31.2%[7] - Revenue from precision marketing and enterprise solutions grew by 29.3% to RMB 372.7 million in 2023[8] - Revenue increased by 31.2% from RMB 314.1 million in 2022 to RMB 412.0 million in 2023, primarily driven by growth in precision marketing and enterprise solutions[22] - Precision marketing and enterprise solutions revenue grew by 29.3% from RMB 288.2 million in 2022 to RMB 372.7 million in 2023, supported by user growth and engagement[23] - Medical knowledge solutions revenue increased by 31.6% from RMB 12.3 million in 2022 to RMB 16.1 million in 2023, due to expanded product offerings and new membership marketing methods[24] - Intelligent patient management solutions revenue surged by 70.2% from RMB 13.6 million in 2022 to RMB 23.2 million in 2023, driven by the success of the single-disease patient management platform[25] - Total revenue for 2023 reached RMB 412.00 million, a 31.2% increase compared to RMB 314.05 million in 2022[61] - Revenue from precision marketing and enterprise solutions grew to RMB 372.69 million in 2023, up from RMB 288.18 million in 2022, a 29.3% increase[65] - Revenue from medical knowledge solutions increased to RMB 16.14 million in 2023, up from RMB 12.26 million in 2022, a 31.6% growth[65] - Revenue from intelligent patient management solutions rose to RMB 23.18 million in 2023, up from RMB 13.62 million in 2022, a 70.2% increase[65] Profit and Margin Performance - Gross profit rose by 18.1% to RMB 251,335 thousand in 2023 from RMB 212,741 thousand in 2022[2] - Net profit attributable to owners of the company surged by 106.5% to RMB 242,301 thousand in 2023 from RMB 117,321 thousand in 2022[2] - Non-HKFRS adjusted net profit grew by 86.8% to RMB 271,093 thousand in 2023 from RMB 145,155 thousand in 2022[2] - Net profit for 2023 was RMB 251.8 million, a significant increase of 99.1% compared to 2022[7] - The net profit margin increased by 20.8 percentage points to 61.1% in 2023[7] - Adjusted net profit for 2023 was RMB 271.1 million, an increase of 86.8% compared to 2022[7] - Gross profit rose by 18.1% from RMB 212.7 million in 2022 to RMB 251.3 million in 2023, with a gross margin decline from 67.7% to 61.0%[27] - Profit before tax surged by 87.5% from RMB 135.0 million in 2022 to RMB 253.1 million in 2023[33] - Net profit for the year increased by 99.1% from RMB 126.4 million in 2022 to RMB 251.8 million in 2023, with net profit margin rising from 40.3% to 61.1%[35][36] - Adjusted net profit increased by 86.8% from RMB 145.2 million in 2022 to RMB 271.1 million in 2023, with adjusted net profit margin rising from 46.2% to 65.8%[37] - Gross profit for 2023 was RMB 251,335 thousand, up from RMB 212,741 thousand in 2022[48] - Net profit for 2023 was RMB 251,760 thousand, more than double the RMB 126,421 thousand in 2022[48] - Basic earnings per share increased to RMB 242,301 thousand in 2023 from RMB 117,321 thousand in 2022, reflecting strong profit growth[79] User and Engagement Metrics - Registered user base grew to 6.8 million in 2023, up from 6.2 million in 2022[4] - Registered physician users increased to 4.0 million in 2023, covering 87% of Chinese practicing physicians[4][5] - Average monthly active users reached 2.40 million in 2023, up from 2.05 million in 2022[4] - Paid clicks increased to 9.7 million in 2023 from 7.2 million in 2022[4] - The number of clients for the precision marketing and enterprise solutions increased by 40.0% to 182 in 2023[8] - The number of products covered by the precision marketing and enterprise solutions increased from 284 in 2022 to 386 in 2023[8] - The number of registered physician users who participated in paid clicks increased from 627,000 in 2022 to 774,000 in 2023[8] - Paid clicks increased from 7.2 million in 2022 to 9.7 million in 2023[8] - The company's chronic disease management platform accumulated approximately 377,000 users and 105,000 participating physicians by the end of 2023[15] Technology and Innovation - The company successfully commercialized generative AI technology, exemplified by the Medlive 3.0 intelligent medical consultant system[6] - The company's clinical research team has expanded significantly, with project management, clinical operations, and data statistics growing rapidly, leveraging digital clinical trial systems to enhance efficiency in clinical research[10] - The company launched a remote intelligent clinical trial system (DCT), patient digital follow-up system, and AI-based journal selection tools, improving efficiency in patient recruitment, data collection, and quality control[10] - The company launched the "e研通" platform to enhance physician research efficiency and upgraded the "论文通" platform with AI-powered SCI journal selection services to improve publication success rates[14] - The company plans to strengthen cross-departmental collaboration using AI and big data to improve service efficiency[19] - The company plans to invest HKD 374.2 million in developing and expanding technology applications, particularly in machine learning, natural language processing, knowledge graphs, and user understanding, with HKD 56.7 million utilized and HKD 317.5 million remaining, expected to be used by December 2027[97] Strategic Investments and Acquisitions - The company plans to continue strategic investments and acquisitions to expand its customer base and enhance technological capabilities[46] - The company acquired 60% equity in Beijing Medicon Information Consulting Co., Ltd. for RMB 100,253,400, with payments made in four installments[44] - The company acquired 50% equity in Shicheng Medical Consulting Co., Ltd. for RMB 65,000,000, with a profit guarantee of RMB 58,080,000 over four years[45] - The company acquired 60% equity in Lingbo Consulting (Shanghai) Co., Ltd. for RMB 33,930,000, with a profit guarantee of RMB 21,720,000 over four years[45] - The company has set aside HKD 2,338.6 million for strategic investments or acquisitions, with HKD 195.8 million utilized and HKD 2,142.8 million remaining[97] Financial Position and Expenses - Other income and gains increased significantly from RMB 75.7 million in 2022 to RMB 188.5 million in 2023, mainly due to higher bank interest income and government subsidies[28] - Sales and distribution expenses grew by 13.4% from RMB 28.9 million in 2022 to RMB 32.8 million in 2023, primarily due to an increase in sales personnel[29] - Administrative expenses increased by 18.0% from RMB 122.4 million in 2022 to RMB 144.5 million in 2023, primarily due to increased platform maintenance and upgrade costs for the medical vertical and higher R&D expenses[30][31] - Financing costs decreased from RMB 0.5 million in 2022 to RMB 0.4 million in 2023, mainly due to reduced lease liability interest[32] - Income tax expenses decreased by 84.1% from RMB 8.6 million in 2022 to RMB 1.4 million in 2023, largely due to increased stock option exercises and tax deductions[34] - Cash and cash equivalents increased to RMB 4,358.3 million in 2023 from RMB 4,187.3 million in 2022, with 36.4% denominated in HKD, 10.5% in RMB, and 53.1% in USD[40] - The company has no short-term or long-term bank borrowings as of December 31, 2023, except for lease liabilities of RMB 8.2 million[41] - The company's asset-liability ratio was zero as of December 31, 2023, with no borrowings[42] - Capital expenditures for 2023 amounted to approximately RMB 88.2 million, a significant increase from RMB 46.0 million in 2022, primarily due to acquisitions and IT equipment expenses[43] - The company had 742 full-time employees as of December 31, 2023, with total employee costs of approximately RMB 159.2 million for the year[47] - Exchange rate differences amounted to 69,317 thousand RMB, with other comprehensive income for the year (after tax) at 63,056 thousand RMB, and total comprehensive income for the year reaching 314,816 thousand RMB[50] - Non-current assets totaled 321,228 thousand RMB, with property, plant, and equipment at 2,620 thousand RMB, and goodwill increasing to 192,525 thousand RMB from 111,518 thousand RMB in the previous year[51] - Current assets amounted to 4,572,588 thousand RMB, with trade receivables at 109,871 thousand RMB and cash and cash equivalents at 4,358,255 thousand RMB[51] - Current liabilities totaled 189,772 thousand RMB, with trade payables at 14,771 thousand RMB and accrued expenses at 135,238 thousand RMB[51] - Non-current liabilities amounted to 58,842 thousand RMB, with contingent consideration payable at 47,663 thousand RMB and deferred tax liabilities at 7,536 thousand RMB[52] - Total equity reached 4,645,202 thousand RMB, with equity attributable to owners of the parent company at 4,597,369 thousand RMB and non-controlling interests at 47,833 thousand RMB[53] - The cost of services provided increased to RMB 160,481 thousand in 2023, up from RMB 101,132 thousand in 2022, representing a 58.7% increase[72] - R&D expenses rose to RMB 54,255 thousand in 2023, compared to RMB 46,231 thousand in 2022, a 17.4% increase[72] - Employee benefits expenses, excluding directors and top executives, totaled RMB 149,102 thousand in 2023, up from RMB 139,470 thousand in 2022, a 6.9% increase[72] - The company's effective tax rate for 2023 was 0.54%, significantly lower than the statutory rate of 25% due to preferential tax rates and other adjustments[76] - Trade receivables increased to RMB 109,871 thousand in 2023 from RMB 95,079 thousand in 2022, with a corresponding increase in impairment allowance to RMB 1,319 thousand[80][82] - The company's total tax expense for 2023 was RMB 1,372 thousand, significantly lower than the RMB 8,616 thousand in 2022 due to various tax adjustments and preferential rates[75] - The expected credit loss rate for trade receivables aged 1 to 2 years and overdue increased from 38.7% in 2022 to 40.3% in 2023, while the total expected credit loss increased from RMB 814,000 in 2022 to RMB 1,319,000 in 2023[84][85] - The total trade receivables increased from RMB 95,893,000 in 2022 to RMB 111,190,000 in 2023, with the highest expected credit loss rate of 100% for receivables aged over 3 years and overdue[84][85] - Trade payables increased significantly from RMB 2,709,000 in 2022 to RMB 14,771,000 in 2023, with the majority (RMB 12,722,000) aged less than three months[86] Dividends and Share Repurchases - The company proposed a final dividend of RMB 12.48 cents per share for 2023, up from RMB 6.54 cents per share in 2022[76] - The company repurchased 100,000 shares at a total cost of HKD 744,945 (approximately RMB 683,000) in October 2023, with the highest price paid per share being HKD 7.48[94] - The company proposed a final dividend of RMB 0.1248 per share (equivalent to HKD 0.1375), payable in HKD to shareholders on the register as of June 3, 2024[91] IPO Proceeds Allocation - The company plans to allocate HKD 280.7 million to improve its medical knowledge solutions and enrich its platform's medical knowledge information and tools, with HKD 36.2 million already utilized and HKD 244.5 million remaining, expected to be used by December 2027[96] - HKD 187.1 million is allocated to enhance patient care services, with HKD 33.7 million utilized and HKD 153.4 million remaining, expected to be used by December 2027[96] - The company has allocated HKD 140.3 million to improve intelligent clinical research solutions, with HKD 36.8 million utilized and HKD 103.5 million remaining, expected to be used by December 2027[96] - HKD 467.7 million is allocated for talent recruitment and collaboration with experts, with HKD 83.6 million utilized and HKD 384.1 million remaining, expected to be used by December 2027[97] - HKD 93.6 million is allocated to establish data centers and enhance IT infrastructure computing and storage capabilities, with HKD 19.1 million utilized and HKD 74.5 million remaining, expected to be used by December 2027[97] - HKD 467.7 million is allocated for general working capital and other corporate purposes, with HKD 106.0 million utilized and HKD 361.7 million remaining[97] - The total IPO proceeds allocated amount to HKD 4,677.3 million, with HKD 640.4 million utilized and HKD 4,036.9 million remaining[97] - The company has not used any IPO proceeds for purchasing or subscribing to financial products, and the unused funds are deposited with licensed financial institutions[97] Geographic Revenue Breakdown - Revenue from mainland China increased to RMB 402.13 million in 2023, up from RMB 296.89 million in 2022, representing a 35.5% year-over-year growth[61] - Overseas revenue decreased to RMB 9.87 million in 2023, down from RMB 17.17 million in 2022, a 42.5% year-over-year decline[61] Other Financial Metrics - Bank interest income surged to RMB 183.88 million in 2023, compared to RMB 66.24 million in 2022, a 177.6% year-over-year growth[70] - Total other income and gains reached RMB 188.48 million in 2023, up from RMB 75.74 million in 2022, a 148.9% increase[70] - The company's remaining performance obligations (unfulfilled or partially unfulfilled) as of December 31, 2023, amounted to RMB 182.30 million, with RMB 114.95 million expected to be recognized within one year and RMB 67.35 million expected to be recognized after one year[69] - The company's subsidiaries primarily engage in precision marketing, enterprise solutions, medical knowledge solutions, and intelligent patient management solutions[54] - The financial statements are prepared in accordance with Hong Kong Financial Reporting Standards (HKFRS) and the disclosure requirements of the Hong Kong Companies Ordinance, using the historical cost convention[55] - The consolidated financial statements include the financial statements of the company and its subsidiaries for the year ended December 31, 2023, with subsidiaries being entities directly or indirectly controlled by the company[56] - The company evaluates control over investees by considering contractual arrangements, rights arising from other contractual arrangements, and voting rights, with changes in control reassessed based on facts and circumstances[57] - The company's subsidiaries in China benefited from preferential tax rates, with some qualifying for a 15% rate as high-tech enterprises and others for a 5% rate as small and micro enterprises[74] - The company's trade receivables are primarily on credit terms of up to 180 days, with overdue balances regularly reviewed by senior management[80]

User Engagement and Platform Growth - As of June 30, 2023, the number of registered users on the Medlive platform reached approximately 6.4 million, with about 3.81 million being licensed physicians, representing approximately 86.6% of the total licensed physicians in China[6]. - The average monthly active users (MAUs) of the Medlive platform in the first half of 2023 reached 2.20 million, indicating a strong user engagement[7]. - As of June 30, 2023, the number of registered users on the Medlive platform reached approximately 6.4 million, with about 3.81 million being practicing physicians in China, representing approximately 86.6% of the total practicing physicians in the country[9]. - The average monthly active users on the Medlive platform reached 2.20 million in the first half of 2023, indicating strong user engagement[9]. Financial Performance - For the six months ended June 30, 2023, the Group's revenue was approximately RMB 173.5 million, reflecting a year-on-year increase of 31.5%[12]. - The net profit for the same period increased by 267.5% to RMB 101.7 million, with the net profit margin rising from approximately 21.0% to approximately 58.6%, an increase of 37.6 percentage points[14]. - The adjusted net profit for the six months ended June 30, 2023, was approximately RMB 119.8 million, representing a 122.0% increase compared to RMB 54.0 million for the same period in 2022[14]. - Revenue increased by approximately 31.5% from approximately RMB132.0 million for the six months ended June 30, 2022, to approximately RMB173.5 million for the same period in 2023, primarily due to growth in precision marketing and corporate solutions[43]. - Revenue from precision marketing and corporate solutions rose by approximately 33.5% from approximately RMB118.4 million for the six months ended June 30, 2022, to approximately RMB158.1 million for the same period in 2023, driven by an increase in the healthcare customer base from 84 to 124[43]. - The Group's profit before tax increased by approximately 202.9% from approximately RMB33.9 million for the six months ended June 30, 2022, to approximately RMB102.7 million for the same period in 2023[55]. - The Group's profit for the period increased by approximately 267.5% from approximately RMB27.7 million for the six months ended June 30, 2022, to approximately RMB101.7 million for the same period in 2023[56]. Strategic Acquisitions and Partnerships - In June 2023, the company acquired a 50% equity interest in Beijing SCMedcon Co., Ltd., expanding its service offerings to pharmaceutical and medical device companies[8]. - The Group acquired a 50% stake in Beijing Shicheng Medical Consulting Co., further expanding its service offerings to pharmaceutical and medical device companies[9]. - The Group acquired 50% equity interests in SCMedcon for a cash consideration of RMB65,000,000 on June 12, 2023[135]. - The acquisition allows the Group to enhance its capabilities in organizing medical exhibitions and providing related services[135]. - The Group's strategy includes pursuing opportunities for management consulting and medical technology services through SCMedcon[135]. Technology and Innovation - The Group continues to invest in AI technology and has established collaborations with various GPT model platforms to enhance its digital marketing solutions[11]. - The Group aims to provide more intelligent services by embedding medical expertise into its business model, enhancing the overall healthcare ecosystem[11]. - The company leverages AI technology to create an analysis and content recommendation engine for physicians' online learning, supporting digital education throughout the product lifecycle[18]. - The Group plans to leverage AI and machine learning to develop innovative research tools, including AI writing assistants, to improve research efficiency for physicians[36]. Market Trends and Industry Insights - The digital marketing of the pharmaceutical industry has rebounded in early 2023, driven by the resumption of regular hospital operations and accelerated drug approval processes[5]. - The Group's performance obligation for application software development services is satisfied over time as services are rendered or at the point in time when services are accepted according to the agreement[110]. - The Group's revenue recognition includes services transferred at a point in time and over time, with total revenue recognition for services at RMB 173,506,000[109]. Research and Development - The company has established the Medlive Oncology Clinical Science Committee, which includes top-tier experts in various cancer fields, to enhance clinical research capabilities[23]. - The company provides customized trial design and monitoring processes for real-world studies (RWS), improving trial efficiency and data quality[22]. - Research and development costs for the six months ended June 30, 2023, were RMB 18,587,000, up from RMB 16,844,000 in 2022, reflecting an increase of approximately 10%[115]. Customer Solutions and Services - The Medlive platform provides high-quality medical content and tools, addressing the needs of physicians in clinical diagnosis, professional learning, and medical research[7]. - The Group offers corporate solutions to improve the efficiency of clinical trials and market research for pharmaceutical and medical device companies[20]. - The Group's intelligent patient management solutions focus on chronic diseases such as breast cancer, lung cancer, and diabetes, with plans for future expansion[33]. Financial Position and Cash Flow - As of June 30, 2023, the Group had cash and cash equivalents of approximately RMB4,373.3 million, compared to approximately RMB4,187.3 million as of December 31, 2022[63]. - The Group's capital expenditure for the six months ended June 30, 2023, was approximately RMB46.7 million, compared to RMB45.6 million for the same period in 2022[67]. - The Group's total comprehensive income for the period was RMB248,494, compared to RMB219,503 in the previous period[78]. - Cash generated from operating activities for the six months ended June 30, 2023, was RMB30,320,000, compared to RMB28,566,000 for the same period in 2022, reflecting an increase of about 6.1%[91]. Shareholder Information and Dividends - The company declared a final dividend of RMB 6,376,000 for the year 2022, which was paid to non-controlling shareholders[88]. - An interim dividend of RMB 10.67 cents per ordinary share was declared on August 29, 2023, amounting to approximately RMB 77,580,000, compared to no interim dividend in the same period of 2022[121]. - The interim dividend will be paid to shareholders whose names appear on the register of members on 13 November 2023, with the register closing from 9 November 2023 to 13 November 2023[197]. Regulatory and Compliance - The provision of medical knowledge solutions involves fees and is subject to PRC regulations on value-added telecommunications[200]. - The Group is engaged in foreign-related market investigation and production of media content, which may be subject to foreign ownership restrictions[200]. - The Group's Internet hospital services and SaaS solutions may also face restrictions on foreign ownership[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 2022年年報補充公告 謹請參閱醫脈通科技有限公司（「本公司」）截至2022年12月31日止年度的年報 （「2022年年報」）。除非另有界定，本公告所用詞彙與2022年年報所界定者具有 相同涵義。本公告旨在為2022年年報提供有關本公司股份獎勵計劃的補充資料。 根據股份獎勵計劃，有500,000份股份獎勵於2022年1月17日授出。股份於2022年 1月14日（即授出日期前一個交易日）的收市價為每股21.90港元。除上述500,000 份股份獎勵外，截至2022年12月31日止財政年度並無授出其他股份獎勵。 於2022年1月1日及2022年12月31日，根據股份獎勵計劃及首次公開發售後購 股權計劃的計劃授權可予授出之股份獎勵及購股權總數分別為69,517,600及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 截至2023年6月30日止六個月的中期業績公告 | --- | --- | --- | --- | --- | |-------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------|----------------------|--------------| | | | | | | | | 財務摘要 | | | | | | | 截至 6 月 30 日止六個月 2023 年 （未經審核） （人 ...

7777777 0010001 日7 medlive.cn Medlive Technology Co., Ltd. 醫 脈 通 科 技 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限責任公司) Stock Code 股份代號 : 2192 Al 007 Contents 目錄 Corporate Information 公司資料 2 Financial Summary 財務摘要 5 Chairman's Statement 董事長報告 6 Business Overview and Outlook 業務概覽及展望 10 Management Discussion and Analysis 管理層討論與分析 20 Directors and Senior Management 董事及高級管理層 32 Report of Directors 董事會報告 41 Corporate Governance Report 企業管治報告 93 Independent Auditor's Report 獨立 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 截至2022年12月31日止年度的年度業績公告 | --- | --- | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------------|---------------------|--------------------|--------------------------------------------| | | | | | | | | 財務摘要 | | | | | | | 截至 月 | 日止年度 | 同比變 ...

Medlive Technology Co., Ltd. 醫脈通科技有限公司 (於開曼群島註冊成立的有限責任公司) (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號 : 2192 2021 ANNUAL REPORT 年報 Contents 目錄 | Corporate Information | 2 | | --- | --- | | 公司資料 | | | Financial Summary | 5 | | 財務摘要 | | | Chairman's Statement | 6 | | 董事長報告 | | | Business Overview and Outlook | 12 | | 業務概覽及展望 | | | Management Discussion and Analysis | 18 | | 管理層討論與分析 | | | Directors and Senior Management | 29 | | 董事及高級管理層 | | | Report of Directors | 38 | | 董事會報告 ...